Literature DB >> 21911660

Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.

Yafei Huang1, Rachel Potter, Wendy Sigurdson, Anna Santacruz, Shirley Shih, Yo-El Ju, Tom Kasten, John C Morris, Mark Mintun, Stephen Duntley, Randall J Bateman.   

Abstract

BACKGROUND: The amyloid hypothesis predicts that increased production or decreased clearance of β-amyloid (Aβ) leads to amyloidosis, which ultimately culminates in Alzheimer disease (AD).
OBJECTIVE: To investigate whether dynamic changes in Aβ levels in the human central nervous system may be altered by aging or by the pathology of AD and thus contribute to the risk of AD.
DESIGN: Repeated-measures case-control study.
SETTING: Washington University School of Medicine in St Louis, Missouri. PARTICIPANTS: Participants with amyloid deposition, participants without amyloid deposition, and younger normal control participants. MAIN OUTCOME MEASURES: In this study, hourly cerebrospinal fluid (CSF) Aβ concentrations were compared with age, status of amyloid deposition, electroencephalography, and video recording data.
RESULTS: Linear increases were observed over time in the Aβ levels in CSF samples obtained from the younger normal control participants and the older participants without amyloid deposition, but not from the older participants with amyloid deposition. Significant circadian patterns were observed in the Aβ levels in CSF samples obtained from the younger control participants; however, circadian amplitudes decreased in both older participants without amyloid deposition and older participants with amyloid deposition. Aβ diurnal concentrations were correlated with the amount of sleep but not with the various activities that the participants participated in while awake.
CONCLUSIONS: A reduction in the linear increase in the Aβ levels in CSF samples that is associated with amyloid deposition and a decreased CSF Aβ diurnal pattern associated with increasing age disrupt the normal physiology of Aβ dynamics and may contribute to AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911660      PMCID: PMC3254706          DOI: 10.1001/archneurol.2011.235

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  23 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  APP processing and synaptic function.

Authors:  Flavio Kamenetz; Taisuke Tomita; Helen Hsieh; Guy Seabrook; David Borchelt; Takeshi Iwatsubo; Sangram Sisodia; Roberto Malinow
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

Review 3.  Chronobiology.

Authors:  F Halberg
Journal:  Annu Rev Physiol       Date:  1969       Impact factor: 19.318

4.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

Review 5.  Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Authors:  T E Golde; C B Eckman; S G Younkin
Journal:  Biochim Biophys Acta       Date:  2000-07-26

6.  Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Authors:  Kwasi G Mawuenyega; Wendy Sigurdson; Vitaliy Ovod; Ling Munsell; Tom Kasten; John C Morris; Kevin E Yarasheski; Randall J Bateman
Journal:  Science       Date:  2010-12-09       Impact factor: 47.728

7.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.

Authors:  A Goate; M C Chartier-Harlin; M Mullan; J Brown; F Crawford; L Fidani; L Giuffra; A Haynes; N Irving; L James
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

8.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

9.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

10.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

Authors:  M Kanai; E Matsubara; K Isoe; K Urakami; K Nakashima; H Arai; H Sasaki; K Abe; T Iwatsubo; T Kosaka; M Watanabe; Y Tomidokoro; M Shizuka; K Mizushima; T Nakamura; Y Igeta; Y Ikeda; M Amari; T Kawarabayashi; K Ishiguro; Y Harigaya; K Wakabayashi; K Okamoto; S Hirai; M Shoji
Journal:  Ann Neurol       Date:  1998-07       Impact factor: 10.422

View more
  107 in total

Review 1.  SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases.

Authors:  Ross W Paterson; Audrey Gabelle; Brendan P Lucey; Nicolas R Barthélemy; Claire A Leckey; Christophe Hirtz; Sylvain Lehmann; Chihiro Sato; Bruce W Patterson; Tim West; Kevin Yarasheski; Jonathan D Rohrer; Norelle C Wildburger; Jonathan M Schott; Celeste M Karch; Selina Wray; Timothy M Miller; Donald L Elbert; Henrik Zetterberg; Nick C Fox; Randall J Bateman
Journal:  Nat Rev Neurol       Date:  2019-06-20       Impact factor: 42.937

2.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

Authors:  Yan Q Chen; Jason S Troutt; Robert J Konrad
Journal:  Lipids       Date:  2014-05       Impact factor: 1.880

Review 4.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

Review 5.  Sleep in older adults and in subjects with dementia.

Authors:  Helmut Frohnhofen; Jeanina Schlitzer; Nikolaus Netzer
Journal:  Z Gerontol Geriatr       Date:  2017-07-18       Impact factor: 1.281

Review 6.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

7.  Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.

Authors:  Ricardo S Osorio; Indu Ayappa; Janna Mantua; Tyler Gumb; Andrew Varga; Anne M Mooney; Omar E Burschtin; Zachary Taxin; Emmanuel During; Nicole Spector; Milton Biagioni; Elizabeth Pirraglia; Hiuyan Lau; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; David M Rapoport; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

8.  β-amyloid dynamics in human plasma.

Authors:  Yafei Huang; Rachel Potter; Wendy Sigurdson; Tom Kasten; Rose Connors; John C Morris; Tammie Benzinger; Mark Mintun; Tim Ashwood; Mats Ferm; Samantha L Budd; Randall J Bateman
Journal:  Arch Neurol       Date:  2012-12

9.  Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.

Authors:  Ricardo S Osorio; Emma L Ducca; Margaret E Wohlleber; Emily B Tanzi; Tyler Gumb; Akosua Twumasi; Samuel Tweardy; Clifton Lewis; Esther Fischer; Viachaslau Koushyk; Maria Cuartero-Toledo; Mohammed O Sheikh; Elizabeth Pirraglia; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; Sonja Schuetz; Andrew W Varga; Indu Ayappa; David M Rapoport; Mony J de Leon
Journal:  Sleep       Date:  2016-06-01       Impact factor: 5.849

10.  Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly.

Authors:  Andrew W Varga; Margaret E Wohlleber; Sandra Giménez; Sergio Romero; Joan F Alonso; Emma L Ducca; Korey Kam; Clifton Lewis; Emily B Tanzi; Samuel Tweardy; Akifumi Kishi; Ankit Parekh; Esther Fischer; Tyler Gumb; Daniel Alcolea; Juan Fortea; Alberto Lleó; Kaj Blennow; Henrik Zetterberg; Lisa Mosconi; Lidia Glodzik; Elizabeth Pirraglia; Omar E Burschtin; Mony J de Leon; David M Rapoport; Shou-En Lu; Indu Ayappa; Ricardo S Osorio
Journal:  Sleep       Date:  2016-11-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.